Bio-Techne Corp.
Bio-Techne Corporation (TECH)
Overview
Bio-Techne is a life-sciences company that develops, manufactures, and sells biological reagents, instruments, and diagnostic products used in scientific research, drug development, bioprocessing, and clinical diagnostics. Headquartered in Minneapolis, Minnesota, it sits in the Health Care sector under life-sciences tools and diagnostics, and trades on Nasdaq. For fiscal year 2026 (ended June 30, 2026), the company reported total revenue of roughly $1.22 billion and employs around 3,000 people. Bio-Techne is currently the subject of a pending acquisition: on June 25, 2026, it agreed to be acquired by Germany's Merck KGaA for $73 per share in cash, an all-cash deal valuing the company at an enterprise value of approximately $11.3 billion, with the transaction expected to close in late 2026 or early 2027.
What They Do & How They Make Money
Bio-Techne makes money selling the tools and materials that scientists, biopharma companies, and clinical labs need to study, measure, and manipulate proteins and other biomolecules. Its core, highest-margin business sells consumable reagents — antibodies, recombinant proteins, cytokines, growth factors, and assay kits, sold mainly under the R&D Systems and Novus Biologicals brands — to academic researchers and biopharmaceutical companies who use them repeatedly in experiments, a recurring-purchase, razor/razorblade-adjacent model similar to lab-supply peers. It also sells analytical instruments (such as the Ella and Simple Western/ProteinSimple platforms) that, once installed in a customer's lab, generate a long tail of consumable and service revenue as researchers keep buying reagents and cartridges to run on that hardware. A fast-growing part of the business is spatial biology — instruments and reagent kits (its RNAscope in-situ hybridization technology and the COMET platform) that let researchers see where specific genes or proteins are expressed within intact tissue samples, a capability in high demand for oncology and translational research. On the diagnostics side, Bio-Techne supplies clinical laboratories with molecular diagnostic kits, quality-control materials, and contract/custom manufacturing of diagnostic components, and it also sells GMP-grade proteins used in cell and gene therapy manufacturing, a higher-growth niche tied to the expansion of biologic and cell-therapy drug production. The company has historically grown significantly through acquisition — it has completed well over a dozen acquisitions since 2013 (including Novus Biologicals, ProteinSimple, Advanced Cell Diagnostics, Exosome Diagnostics, and Asuragen) to build out its reagents, spatial biology, and diagnostics capabilities.
Business Segments
Bio-Techne reports results across two primary operating segments:
- Protein Sciences — the larger segment (roughly $875 million in FY2026 revenue, about 72% of the total), built around the R&D Systems and Novus Biologicals antibody/protein reagent brands, ProteinSimple analytical instruments (Simple Western, Ella immunoassay platform), and GMP-grade bioprocessing proteins used in cell and gene therapy manufacturing.
- Diagnostics and Spatial Biology (also referred to as Diagnostics and Genomics; roughly $336 million in FY2026 revenue, about 28% of the total) — combines Bio-Techne Spatial (RNAscope in-situ hybridization technology and the COMET platform for tissue-based biomarker discovery) with Bio-Techne Diagnostics (molecular diagnostic kits, quality controls, and contract assay-development/manufacturing services for clinical labs, built substantially from the Exosome Diagnostics and Asuragen acquisitions).
A small "Other" category captures minor remaining revenue not allocated to the two main segments.
Competitors
Bio-Techne competes against a mix of large diversified life-sciences tools companies and more focused specialty players:
- Broad life-science reagents & tools: Thermo Fisher Scientific, Danaher (through subsidiaries like Cytiva and Leica Biosystems), Merck KGaA's own MilliporeSigma life-science business (notably its acquirer), Agilent Technologies, and Bio-Rad Laboratories.
- Spatial biology specifically: 10x Genomics, NanoString (now part of Bruker), Akoya Biosciences, and Standard BioTools compete directly with Bio-Techne Spatial's RNAscope and COMET platforms.
- Antibodies and protein reagents: Abcam (part of Danaher), Cell Signaling Technology, and Sino Biological compete in the core antibody/protein reagent market.
- Diagnostics/molecular testing components: Roche Diagnostics, Qiagen, and other molecular-diagnostics kit and reagent suppliers compete with Bio-Techne Diagnostics.
Competitive Position
Bio-Techne's competitive strength rests on the quality and reputation of its foundational R&D Systems brand, which is one of the most established and trusted names among researchers for high-purity cytokines, growth factors, and antibodies — attributes that matter enormously in a field where reagent quality and lot-to-lot consistency directly affect experimental reproducibility. Its instrument platforms (Simple Western, Ella, COMET) create a "razor and razorblade" dynamic that locks in recurring, high-margin consumable revenue once a lab has adopted the hardware, and its RNAscope spatial biology technology is a widely cited, well-validated method that has helped the company build a leadership position in the fast-growing spatial biology tools market — a segment posting double-digit organic growth even as legacy reagent sales grow more modestly. The GMP protein manufacturing business ties Bio-Techne into the expanding cell and gene therapy manufacturing supply chain, a structurally growing end market. The pending $73/share, ~$11.3 billion acquisition by Merck KGaA (announced June 2026, a roughly 36% premium to Bio-Techne's prior one-month volume-weighted average share price) validates this strategic positioning — Merck KGaA is targeting roughly €140 million in annual run-rate cost synergies by the third year post-close and expects the deal to be immediately accretive to sales growth and EBITDA margin, reflecting the complementary fit between Bio-Techne's reagents/spatial biology/diagnostics portfolio and Merck's existing MilliporeSigma life-science business.
Key risks and challenges facing the company (and by extension, the pending combination) include a period of subdued organic growth and margin compression in the larger, more mature Protein Sciences segment as academic and biopharma research funding has been under pressure; the general cyclicality of life-sciences tools spending, which is tied to NIH/government research funding levels, biopharma R&D budgets, and venture funding for biotech; and intensifying competition in spatial biology from well-funded rivals like 10x Genomics. As of early September 2026, the acquisition remains pending regulatory approval and deal closing (expected late 2026/early 2027), and Bio-Techne has already suspended its quarterly investor earnings calls in light of the transaction — meaning integration execution risk and deal-completion risk (regulatory review, financing) are now the dominant near-term considerations for the company, alongside the normal competitive and end-market risks of its business.